You are here

Article Text

Article menu

other Versions

Download PDFPDF
Clinical science
Central serous chorioretinopathy imaging biomarkers
  1. Sumit Randhir Singh1,
  2. Claudio Iovino2,
  3. Dinah Zur3,
  4. Dua Masarwa4,
  5. Matias Iglicki5,
  6. Ramkailash Gujar6,
  7. Marco Lupidi7,
  8. Dmitrii S Maltsev8,
  9. Elodie Bousquet9,
  10. Mehdi Bencheqroun10,
  11. Francesca Amoroso11,
  12. Luiz H Lima12,
  13. Srikanta Kumar Padhy13,
  14. Vishal Govindahari14,
  15. Khushboo Chandra15,
  16. Eric H Souied16,
  17. Francisco J Rodriguez17,
  18. Laura A Daza17,
  19. Hernan A Rios17,
  20. Carlo Cagini18,
  21. Enrico Peiretti19,
  22. Francine Behar-Cohen20,
  23. Jay Chhablani21
  1. 1Jacobs Retina Center, University of California San Diego, La Jolla, California, USA
  2. 2Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, University Federico II, Marano, Italy
  3. 3Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  4. 4Department of Ophthalmology, Barzilai University Medical Center, Ashkelon, Israel
  5. 5Private Retina Service, University of Buenos Aires, Buenos Aires, Argentina
  6. 6Department of Surgical and Biomedical Sciences, Section of Ophthalmology, University of Perugia, Perugia, Italy
  7. 7Department of Ophthalmology, University of Perugia, Perugia, Italy
  8. 8Ophthalmology, Military Maedical Academy, Saint Petersburg, Russian Federation
  9. 9Ophthalmology, Hopital Cochin, Paris, France
  10. 10Ophtalmopôle, Cochin Hospital, Paris Descartes University, Paris, France
  11. 11Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Université Paris Est, Creteil, France
  12. 12Ophthalmology, Federal University of Sao Paulo, São Paulo, Brazil
  13. 13Ophthalmology, AIIMS, New Delhi, India
  14. 14Retina and Uveitis Service, L V Prasad Eye Institute, MTC Campus, Bhubaneswar, India
  15. 15Dept. of Vitreoretina, Disha Eye Hospitals Pvt Ltd, Kolkata, India
  16. 16Ophthalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  17. 17Fundacion Oftalmologica Nacional, Universidad del Rosario, Bogota, Colombia
  18. 18Department of Biomedical and Surgical Sciences, University of Perugia School of Medicine and Surgery, Perugia, Italy
  19. 19Eye Clinic, Universita degli Studi di Cagliari, Cagliari, Italy
  20. 20Team 17, INSERM UMR1138, Paris, France
  21. 21UPMC Eye Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
  1. Correspondence to Dr Jay Chhablani, UPMC Eye Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA; jay.chhablani{at}gmail.com

Abstract

Purpose To identify the factors predicting the visual and anatomical outcomes in eyes with central serous chorioretinopathy (CSCR) through 12 months.

Methods Patients with diagnosis of CSCR, either acute or chronic, were included in this multicentric, retrospective study. Demographic factors; systemic risk factors; central macular thickness (CMT), subfoveal choroidal thickness (SFCT), linear extent of ellipsoid zone (EZ) and interdigitation zone damage on optical coherence tomography; details of leak on fluorescein angiography and indocyanine green angiography were included as predictors of anatomical and visual outcomes. Regression analysis was performed to correlate the changes in best corrected visual acuity (BCVA) and resolution of disease activity.

Results A total of 231 eyes of 201 patients with a mean age (49.7±11.8 years) were analysed. A total of 97 and 134 eyes were classified as acute and chronic CSCR. BCVA (0.35±0.31 to 0.24±0.34; p<0.001), baseline optical coherence tomography (OCT) parameters including CMT (p<0.001), subretinal fluid (SRF) height (p<0.001) and SFCT (p=0.05) showed a significant change through 12 months. Multivariate regression analysis showed change in CMT (p≤0.01) and SRF height at baseline (p=0.05) as factors predictive of good visual outcome. Logistic regression analysis revealed changes in both CMT (p=0.009) and SFCT (p=0.01) through 12 months to correlate with the resolution of disease.

Conclusion OCT parameters such as changes in both CMT and SFCT along with subfoveal EZ damage can be predictive of disease resolution whereas changes in CMT and baseline SRF height correlate well with changes in BCVA through 12 months.

  • treatment medical
  • imaging

https://doi.org/10.1136/bjophthalmol-2020-317422

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors Design: SRS, CI, DZ, VG, EHS, CC, EP, FB-C, JC. Data collection: DZ, DM, MI, RG, ML, DSM, FA, LHL, SKP, KC, FJR, LAD, HAR, EB, MB. Data interpretation and analysis: SRS, DZ, CI, VG, JC, EB, MB. Manuscript writing: SRS, CI, DZ, MI, ML, VG, LAD, HAR. SRS, CI, DZ, EB, MB, VG, EHS, CC, EP, FB-C, JC, DM, MI, RG, ML, DSM, FA, LHL, SKP, KC, FJR, LAD, HAR reviewed the article. All the authors conducted the study and equally contributed in the preparation, review and approval of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Ethics approval Institutional review board (IRB) approval was obtained at all the study sites. The study adhered to tenets of Declaration of Helsinki. A written, informed consent was obtained from all the study participants.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data availability statement Data are available upon reasonable request.

    Linked Articles

    • At a glance
      Highlights from this issue
      Frank Larkin
      British Journal of Ophthalmology 2022; 106 i-ii Published Online First: 22 Mar 2022. doi: 10.1136/bjophthalmol-2022-321436